Market revenue in 2023 | USD 61.8 million |
Market revenue in 2030 | USD 126.5 million |
Growth rate | 10.8% (CAGR from 2023 to 2030) |
Largest segment | Synthetic cpps |
Fastest growing segment | Protein-Derived CPPs |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Protein-Derived CPPs, Synthetic CPPs, Chimeric CPPs |
Key market players worldwide | Biosynth, Creative Peptides, Cupid Peptides, Alta Bioscience Ltd, AnaSpec, Peptomyc, Sarepta Therapeutics Inc, Revance Therapeutics Inc, PolyPeptide Group AG, Bachem Holding AG |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell penetrating peptide market will help companies and investors design strategic landscapes.
Synthetic cpps was the largest segment with a revenue share of 54.85% in 2023. Horizon Databook has segmented the UK cell penetrating peptide market based on protein-derived cpps, synthetic cpps, chimeric cpps covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the UK cell penetrating peptide market, including forecasts for subscribers. This country databook contains high-level insights into UK cell penetrating peptide market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related industry reports found.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account